Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Terminated 3Active not recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other hematologic neoplasm 1Lymphoid 1

Conditions

Carcinoma, Non-Small-Cell Lung 78Melanoma 62Squamous Cell Carcinoma of Head and Neck 46Breast Neoplasms 37Neoplasm Metastasis 34Parkinson Disease 4, Autosomal Dominant Lewy Body 32Carcinoma, Renal Cell 30Lung Neoplasms 29Colorectal Neoplasms 29Neoplasms 25Ovarian Neoplasms 24Triple Negative Breast Neoplasms 22Head and Neck Neoplasms 22Stomach Neoplasms 17Urinary Bladder Neoplasms 16Endometrial Neoplasms 15Carcinoma, Transitional Cell 15Pancreatic Neoplasms 13Prostatic Neoplasms 11Uterine Cervical Neoplasms 10Sarcoma 10Esophageal Neoplasms 10Small Cell Lung Carcinoma 9Recurrence 9Glioblastoma 8Fallopian Tube Neoplasms 8Carcinoma, Squamous Cell 8Carcinoma 8Skin Neoplasms 7Oropharyngeal Neoplasms 7

Interventions

Cyclophosphamide 35fludarabine 18Methotrexate 17fludarabine phosphate 16Dexamethasone 16blinatumomab 15Vincristine 15Cytarabine 14Melphalan 12Tacrolimus 11Etoposide 11pegaspargase 10Whole-Body Irradiation 9Mercaptopurine 9Calcium Dobesilate 9merphos 8Dasatinib 8Busulfan 8Asparaginase 8Thiotepa 7Prednisone 7Mycophenolic Acid 7Leucovorin 7Granulocyte Colony-Stimulating Factor 7Doxorubicin 7prednylidene 6ponatinib 6calaspargase pegol 6Stem Cell Transplantation 6Specimen Handling 6

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Active not recruiting × Precursor Cell Lymphoblastic Leukemia-Lymphoma × pembrolizumab × Clear all
NCT03512405 2025-05-30

Pembrolizumab and Blinatumomab in Treating Participants With Recurrent or Refractory Acute Lymphoblastic Leukemia

City of Hope Medical Center

Phase 1/2 Active not recruiting
36 enrolled
LymphoidOther hematologic neoplasm

Precursor Cell Lymphoblastic Leukemia-Lymphoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡